Your browser is no longer supported. Please, upgrade your browser.
ZLAB [NASD]
Zai Lab Limited
Index- P/E- EPS (ttm)-3.40 Insider Own1.18% Shs Outstand73.85M Perf Week-8.45%
Market Cap13.56B Forward P/E- EPS next Y-3.12 Insider Trans0.00% Shs Float59.71M Perf Month-7.53%
Income-240.40M PEG- EPS next Q-0.99 Inst Own65.80% Short Float2.73% Perf Quarter36.87%
Sales28.80M P/S470.96 EPS this Y-14.60% Inst Trans6.07% Short Ratio4.49 Perf Half Y81.76%
Book/sh6.30 P/B23.49 EPS next Y0.30% ROA-55.20% Target Price155.52 Perf Year163.22%
Cash/sh5.06 P/C29.26 EPS next 5Y- ROE-64.50% 52W Range43.06 - 193.54 Perf YTD9.36%
Dividend- P/FCF- EPS past 5Y- ROI-67.50% 52W High-26.11% Beta1.13
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin72.70% 52W Low232.09% ATR10.05
Employees692 Current Ratio8.60 Sales Q/Q461.80% Oper. Margin- RSI (14)37.55 Volatility8.26% 5.36%
OptionableYes Debt/Eq0.01 EPS Q/Q1.50% Profit Margin- Rel Volume1.12 Prev Close148.01
ShortableYes LT Debt/Eq0.00 EarningsMar 01 BMO Payout- Avg Volume363.31K Price143.00
Recom1.60 SMA20-16.12% SMA50-9.64% SMA20038.72% Volume164,669 Change-3.38%
Apr-28-20Initiated Goldman Buy
Apr-15-20Initiated Guggenheim Buy $75
Jul-12-19Initiated BofA/Merrill Buy
Jul-05-19Initiated Macquarie Outperform
Jan-29-19Initiated Credit Suisse Outperform
Nov-21-18Initiated Jefferies Buy
Jun-21-18Resumed Leerink Partners Outperform $43
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Oct-16-17Initiated Leerink Partners Outperform $42
Oct-16-17Initiated JP Morgan Neutral $32
Mar-02-21 11:56PM  
Mar-01-21 07:00AM  
Feb-27-21 09:23AM  
Feb-18-21 07:31AM  
Jan-28-21 07:30AM  
Jan-11-21 06:45AM  
04:30AM  
Jan-06-21 04:01PM  
Dec-30-20 07:30AM  
06:05AM  
Dec-29-20 08:09AM  
Dec-28-20 07:00PM  
07:30AM  
Dec-16-20 08:15PM  
Dec-01-20 07:30AM  
Nov-11-20 08:30AM  
Nov-10-20 07:00PM  
Oct-29-20 07:30AM  
Oct-28-20 03:18PM  
07:30AM  
Oct-09-20 08:48AM  
Oct-06-20 07:30AM  
Oct-05-20 07:30AM  
Sep-28-20 08:35PM  
07:30AM  
Sep-27-20 11:26PM  
11:21PM  
Sep-22-20 07:53AM  
06:34AM  
Sep-19-20 07:30AM  
Sep-17-20 05:30AM  
Sep-16-20 07:15AM  
Sep-10-20 09:18AM  
07:30AM  
Sep-03-20 07:30AM  
Aug-31-20 07:30AM  
Aug-19-20 10:26AM  
Aug-17-20 07:30AM  
Aug-13-20 08:00PM  
10:38AM  
07:30AM  
Aug-04-20 07:30AM  
Aug-02-20 09:08AM  
Jul-30-20 07:30AM  
Jul-20-20 10:39AM  
07:30AM  
Jul-16-20 06:31PM  
Jul-07-20 11:37PM  
07:30AM  
Jun-17-20 02:03PM  
May-28-20 07:05PM  
07:37AM  
May-27-20 07:30AM  
May-18-20 09:45PM  
07:30AM  
May-13-20 10:10AM  
May-11-20 11:14AM  
May-08-20 01:18PM  
May-06-20 07:30AM  
Apr-30-20 07:30AM  
Apr-16-20 07:30AM  
Apr-08-20 06:00AM  
Mar-28-20 09:09PM  
Mar-19-20 12:21PM  
11:30AM  
07:30AM  
06:30AM  
Mar-16-20 07:30AM  
Mar-05-20 07:30AM  
Feb-11-20 07:30AM  
07:23AM  
06:47AM  
Feb-10-20 07:30AM  
Feb-04-20 07:30AM  
Jan-27-20 04:30PM  
Jan-22-20 09:43PM  
Jan-21-20 04:34PM  
Jan-14-20 07:30AM  
Jan-09-20 07:30AM  
Dec-30-19 06:55AM  
Dec-27-19 08:46AM  
07:41AM  
Dec-23-19 07:30AM  
Dec-16-19 07:30AM  
Dec-08-19 06:26PM  
Oct-30-19 07:30AM  
Oct-27-19 04:16PM  
Oct-25-19 08:30AM  
Oct-24-19 08:30AM  
Oct-04-19 07:30AM  
Sep-29-19 02:15PM  
Sep-11-19 12:22PM  
Sep-03-19 06:01PM  
07:32AM  
06:30AM  
Aug-27-19 07:30AM  
Aug-26-19 07:30AM  
Aug-20-19 07:30AM  
Aug-12-19 07:30AM  
07:30AM  
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.